US FDA Ditches Warnings on Hormone Therapy for Menopause Symptoms, Aiming to Boost Usage.
The Food and Drug Administration (FDA) has decided to remove the black box warnings associated with hormone replacement therapy (HRT), citing outdated information that may have scared off patients from utilizing these treatments to alleviate symptoms of menopause and perimenopause.
This decision was made in an effort to correct what FDA officials described as "misinformation" about HRT's potential risks, including breast cancer, heart disease, and dementia. The warnings were linked to the Women's Health Initiative (WHI), a 2002 study that suggested HRT might increase cancer risk.
However, subsequent research has raised concerns over the design of WHI and its conclusions. Consequently, an FDA expert panel was convened in July to assess the use of hormone therapy in menopause treatment, with public comments solicited. In response to the comments, medical associations such as the American Urogynecologic Society and the American College of Obstetricians and Gynecologists expressed support for revising the labels.
Alicia Jackson, director of the Advanced Research Projects Agency for Health, praised the FDA's decision, highlighting estrogen's importance in women's health. The updated labels will now recommend hormone therapy for patients under 60 or within ten years of menopause onset, except for estrogen-only products which carry a warning about endometrial cancer.
The FDA has also approved two new treatments β a generic version of Premarin and non-hormonal medication for hot flashes. Hormone replacement therapy aims to replace estrogen lost after menopause, available in systemic therapy and low-dose vaginal estrogen forms. The decision may lead to increased usage of hormone therapy, which is essential for maintaining women's overall health.
The move reflects a shift towards a more nuanced understanding of hormone therapy risks, aiming to empower millions of women to live healthier lives.
The Food and Drug Administration (FDA) has decided to remove the black box warnings associated with hormone replacement therapy (HRT), citing outdated information that may have scared off patients from utilizing these treatments to alleviate symptoms of menopause and perimenopause.
This decision was made in an effort to correct what FDA officials described as "misinformation" about HRT's potential risks, including breast cancer, heart disease, and dementia. The warnings were linked to the Women's Health Initiative (WHI), a 2002 study that suggested HRT might increase cancer risk.
However, subsequent research has raised concerns over the design of WHI and its conclusions. Consequently, an FDA expert panel was convened in July to assess the use of hormone therapy in menopause treatment, with public comments solicited. In response to the comments, medical associations such as the American Urogynecologic Society and the American College of Obstetricians and Gynecologists expressed support for revising the labels.
Alicia Jackson, director of the Advanced Research Projects Agency for Health, praised the FDA's decision, highlighting estrogen's importance in women's health. The updated labels will now recommend hormone therapy for patients under 60 or within ten years of menopause onset, except for estrogen-only products which carry a warning about endometrial cancer.
The FDA has also approved two new treatments β a generic version of Premarin and non-hormonal medication for hot flashes. Hormone replacement therapy aims to replace estrogen lost after menopause, available in systemic therapy and low-dose vaginal estrogen forms. The decision may lead to increased usage of hormone therapy, which is essential for maintaining women's overall health.
The move reflects a shift towards a more nuanced understanding of hormone therapy risks, aiming to empower millions of women to live healthier lives.